.World Health Association. Being overweight as well as obese. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Illness Danger Factor Partnership. Worldwide fads in skinny and weight problems from 1990 to 2022: a pooled evaluation of 3663 population-representative research studies with 222 million little ones, youngsters, and also adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google Scholaru00c2.Worldwide Problem Condition Collaborators. Global, local, and also national burden of diabetes from 1990 to 2021, with estimates of frequency to 2050: an organized evaluation for the Global Problem of Disease Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google.com Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Globe Renal Time Steering Committee. Excessive weight and kidney ailment: concealed repercussions of the epidemic. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
A step-by-step assessment and also meta-analysis advises weight problems forecasts onset of persistent kidney health condition in the general population. Renal Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et al. Obesity and persistent renal health condition.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., carry out Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Being overweight, kidney disorder and hypertension: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kidney Illness: Improving Worldwide Outcomes CKD Workplace Group.
KDIGO 2024 Medical Process Tip for the analysis and monitoring of constant renal condition. Kidney Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Kidney Illness: Improving International Results Diabetes Mellitus Workplace Team. KDIGO 2022 Professional Process Guideline for diabetes administration in persistent renal condition. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et al.
Early improvement in albuminuria along with canagliflozin forecasts renal and also cardio outcomes: an article hoc analysis from the support trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.de Zeeuw, D. et cetera. Proteinuria, a target for renoprotection in clients with kind 2 diabetic nephropathy: courses from RENAAL.
Kidney Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. et cetera. Is actually a decline in albuminuria connected with kidney as well as cardio protection?
An article hoc evaluation of the height trial. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic renal ailment: a testimonial of their renal as well as heart protection. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et cetera. GLP-1 as well as the renal: from anatomy to pharmacology as well as results in diabetic issues.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et cetera. Semaglutide and also heart results in people along with style 2 diabetic issues. N.
Engl. J. Medication.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide and also heart outcomes in being overweight without diabetes mellitus. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et cetera.
Results of semaglutide on severe kidney ailment in people along with kind 2 diabetes mellitus. N. Engl.
J. Med. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Colhoun, H. M. et al.
Lasting kidney results of semaglutide in being overweight and also cardiovascular disease in the SELECT trial. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Results of semaglutide on albuminuria and also kidney functionality in people along with obese or obesity along with or even without type 2 diabetic issues: prolegomenous evaluation from the measure 1, 2, as well as 3 trials.
Diabetes mellitus Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Witch Doctor, A. M.
et al. Result of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney results in people with type 2 diabetes: pooled analysis of SUSTAIN 6 and innovator. Flow 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et cetera.
Impact of semaglutide on kidney functionality throughout various degrees of baseline HbA1c, blood pressure, body system weight as well as albuminuria in SUSTAIN 6 and leader 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus the hormone insulin glargine in patients with type 2 diabetes as well as moderate-to-severe severe renal ailment (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetic Issues Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Change in albuminuria as a surrogate endpoint for development of renal illness: a meta-analysis of treatment impacts in randomised clinical tests. Lancet Diabetes Mellitus Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et cetera. Effects of semaglutide along with and without coupled with SGLT2 inhibitor usage in individuals with type 2 diabetes as well as constant renal ailment in the FLOW test. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney as well as safety end results with GLP-1 receptor agonists alone and also in combo with SGLT2 preventions in type 2 diabetic issues: a step-by-step evaluation as well as meta-analysis.
Flow https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et al. Efficiency and protection of SGLT2 preventions along with and also without glucagon-like peptide 1 receptor agonists: a SMART-C collective meta-analysis of randomised controlled tests. Lancet Diabetes Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Results of tirzepatide versus insulin glargine on renal results in style 2 diabetic issues in the SURPASS-4 trial: post-hoc evaluation of an open-label, randomised, phase 3 trial.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et cetera. Body weight and eGFR throughout dulaglutide treatment in kind 2 diabetic issues and also moderate-to-severe constant kidney ailment (AWARD-7).
Diabetic issues Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et cetera. Effects of tirzepatide versus blood insulin glargine on cystatin c-based renal functionality: a SURPASS-4 article hoc analysis. Diabetes Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Diabetes Care (American Diabetes mellitus Organization, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Results of bariatric surgical operation on kidney functionality in overweight individuals: an organized review and meta review.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et al. The impacts of bariatric surgery on kidney results: an organized examine and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et cetera. The determined glomerular filtration cost (mGFR) before and also 6 months after bariatric surgical procedure: a captain research. Nephrol.
Ther. Thirteen, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et al. Adiponectin lessens glomerular endothelial glycocalyx disruption and also repairs glomerular obstacle functionality in a computer mouse model of style 2 diabetic issues. Diabetic issues 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration related to diabetes mellitus and also being overweight in individual condition. World J.
Diabetes Mellitus 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Chagnac, A. & Friedman, A.
N. Measuring albuminuria in individuals with excessive weight: mistakes of the urinary albumin-creatinine proportion. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Wilding, J. P.
H. et cetera. Once-weekly semaglutide in grownups with overweight or excessive weight.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Levey, A.
S. et cetera. A more exact procedure to approximate glomerular purification rate coming from lotion creatinine: a brand-new forecast formula.
Customization of Diet Regimen in Renal Disease Study Hall. Ann. Trainee.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS strategy for iohexol decision in individual EDTA and lithium-heparin plasma, human urine and also in goat- and also pig EDTA plasma. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K. R. et cetera.
Efficacy and safety and security of aldosterone synthase inhibition along with and without empagliflozin for chronic kidney health condition: a randomised, handled, stage 2 trial. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et al. Effectiveness of an unfamiliar inhibitor of general adherence protein-1 in minimizing albuminuria in patients along with diabetic person kidney condition (CD): a randomised, placebo-controlled, period 2 trial. Lancet Diabetic Issues Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in combination along with dapagliflozin compared with dapagliflozin in clients along with chronic kidney health condition (ZENITH-CKD): a multicentre, randomised, active-controlled, period 2b, medical test.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Effect of avenciguat on albuminuria in individuals with CKD: two randomized placebo-controlled tests.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et al.
Sparsentan in patients along with IgA nephropathy: a prespecified meantime analysis as a result of a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.